US · CMND
Clearmind Medicine Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Vancouver, BC V6H 1A5
- Website
- clearmindmedicine.com
Price · as of 2025-10-31
$0.66
Market cap 154.43K
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | $4,200.00 | ||||
| 2023 | $91.20 | ||||
| 2024 | $61.20 | ||||
| 2025 | $2.35 |
AI valuation
Our deep-learning model estimates Clearmind Medicine Inc.'s (CMND) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $0.66
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CMND | Clearmind Medicine Inc. | $0.66 | 154.43K | — | — | — | — | -0.08 | 0.25 | — | 0.94 | — | 0.27 | 0.00% | — | — | -180.28% | 180.16% | -58.05% | 1.49 | -290.07 | 1.22 | 1.21 | 0.58 | -5494.00% | — | -189.00% | -1590.11% | -0.97 | 150.51% | 0.00% | 0.00% | 0.00% | 0.62 | 0.74 | — | -9.25 |
| CNSP | CNS Pharmaceuticals, Inc. | $3.11 | 1.79M | — | — | — | — | -0.68 | 1.63 | — | -0.27 | — | 1.63 | 0.00% | — | — | -1703.39% | 642.50% | -285.68% | 0.05 | -924.50 | 3.43 | 2.91 | 0.41 | -3522.00% | — | 2102.00% | -169.67% | -6.78 | 738.03% | 0.00% | 0.00% | 58.36% | -0.27 | -0.23 | — | -15.99 |
| GRI | GRI Bio, Inc. | $2.55 | 229.07K | +6,695% | — | — | — | -0.02 | 0.04 | — | 0.66 | — | 0.04 | 0.00% | — | — | -238.17% | 791.34% | -166.00% | 0.01 | — | 3.25 | 3.11 | 0.68 | -9212.00% | -10000.00% | 1833.00% | -4086.53% | -3.85 | 673.21% | 0.00% | 0.00% | 1303.49% | 0.66 | 0.78 | — | -12.03 |
| JAGX | Jaguar Health, Inc. | $0.89 | 1.93M | +7,724% | +550% | — | — | -0.11 | 0.58 | 0.36 | -0.89 | — | -0.38 | 83.27% | -263.76% | -329.30% | -637.50% | -86.37% | -74.93% | 5.01 | -133.47 | 1.63 | 0.49 | -0.78 | -9513.00% | 1975.00% | -1091.00% | -697.04% | -1.49 | -82.96% | 0.00% | 0.00% | 49.45% | -1.06 | -1.11 | 2.80 | -10.43 |
| KZIA | Kazia Therapeutics Limite… | $8.45 | 13.69M | +90% | -63% | — | +12,468% | -0.63 | -1.56 | 309.03 | -0.68 | — | -1.38 | 100.00% | -33850.00% | -49290.48% | 226.03% | 112.59% | -149.76% | -0.05 | — | 0.35 | 0.32 | 0.30 | -6564.00% | -9818.00% | 3859.00% | -102.30% | -0.94 | 114.02% | 0.00% | 0.00% | 22.54% | -0.64 | -0.68 | 215.01 | -40.14 |
| SILO | Silo Pharma, Inc. | $0.37 | 2.92M | +5,090% | +86% | — | — | -1.09 | 0.95 | 66.36 | 0.52 | — | 1.00 | 91.90% | -6526.44% | -6092.59% | -78.37% | 266.27% | -57.96% | 0.00 | -925.59 | 4.29 | 4.28 | 0.89 | -83.00% | 0.00% | 1890.00% | -80.13% | -2.32 | 216.94% | 0.00% | 0.00% | 11.59% | 0.49 | 0.60 | -31.84 | -2.88 |
| SNGX | Soligenix, Inc. | $1.18 | 11.9M | — | — | — | — | -0.48 | 0.96 | — | 0.25 | — | 0.96 | 0.00% | — | — | -248.97% | 387.20% | -88.11% | 0.36 | — | 1.82 | 1.61 | 0.67 | -6066.00% | — | -233.00% | -213.60% | -1.73 | 361.77% | 0.00% | 0.00% | 35.16% | 0.25 | 0.29 | — | -38.99 |
| XBIO | Xenetic Biosciences, Inc. | $2.53 | 3.9M | +10,942% | -5% | — | — | -1.47 | 0.97 | 2.32 | 0.09 | — | 0.97 | 100.00% | -168.16% | -158.39% | -50.12% | -1285.35% | -45.24% | 0.00 | — | 7.37 | 6.89 | 1.52 | -517.00% | -156.00% | -3152.00% | -48.55% | -3.15 | -861.34% | 0.00% | 0.00% | 0.00% | 0.09 | 0.13 | -0.14 | -36.77 |
About Clearmind Medicine Inc.
Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
- CEO
- Adi Zuloff-Shani
- Employees
- 4
- Beta
- -1.12
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.66) − 1 = — (DCF, example).